Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: Combination therapy with aerosolized ribavirin and intravenous immunoglobulin

Bone Marrow Transplantation

Volumn 25, Issue 7, 2000, Pages 751-755

  Ghosh, S ^a   Champlin, R E ^a   Englund, J ^b   Giralt, S A ^a   Rolston, K ^a   Raad, I ^a   Jacobson, K ^a   Neumann, J ^a   Ippoliti, C ^a   Mallik, S ^a   Whimbey, E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Respiratory; Ribavirin; Syncytial; Therapy; Transplant; Virus

Indexed keywords

IMMUNOGLOBULIN; RIBAVIRIN;

ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; DISTRESS SYNDROME; DRUG SAFETY; HUMAN; MORTALITY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SOCIAL ISOLATION; UPPER RESPIRATORY TRACT INFECTION; VIRUS PNEUMONIA;

EID: 0034105067     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702228     Document Type: Article

References (34)

1. Englund JA, Sullivan CJ, Jordan C et al. Respiratory syncytial virus infections in immunocompromised adults. Ann Intern Med 1988; 109: 203-208.
2. Martin MA, Bock MJ, Pfaller MA, Wenzel RP. Respiratory syncytial virus infections in adult bone marrow transplant recipients. Lancet 1988; 1: 1396-1397.
3. Hertz MI, Englund JA, Snover D et al. Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature. Medicine 1989; 68: 269-281.
4. Fouillard L, Mouthon L, Laporte JP et al. Severe respiratory syncytial virus pneumonia after autologous bone marrow transplantation: a report of three cases and review. Bone Marrow Transplant 1992; 9: 97-100.
5. Harrington RD, Hooton TM, Hackman RC et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 1992; 165: 987-993.
6. Whimbey E, Champlin RE, Englund JA et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant 1995; 16: 393-399.
7. Whimbey E, Champlin RE, Couch RB et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 1996; 22: 778-782.
8. Whimbey E, Englund JA, Couch RB. Community respiratory virus infections in immunocompromised patients with cancer. Am J Med 1997; 102: 10-18.
9. Bowden RA. Respiratory Virus Infections after Marrow Transplant: The Fred Hutchinson Cancer Research Center Experience. Am J Med 1997; 102: 27-30.
10. Ljungman P. Respiratory virus infections in bone marrow transplant recipients: the European perspective. Am J Med 1997; 102: 44-47.
11. Sparrelid E, Ljungman P, Ekelof-Andstrom E et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant 1997; 19: 905-908.
12. Hall CB, McBride JT, Walsh EE et al. Aerosolized ribavirin treatment of infants with respiratory syncytial virus infection. New Engl J Med 1983; 308: 1443-1447.
13. Liss HP, Bernstein J. Ribavirin aerosol in the elderly. Chest 1988; 93: 1239-1241.
14. Englund JA, Piedra PA, Ahn Y et al. High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection. J Pediatr 1994; 125: 635-641.
15. Ogilvie MM, Vathenen AS, Radford M et al. Maternal antibody and respiratory syncytial virus infection in infancy. J Med Virol 1981; 7: 263-271.
16. Prince GA, Hemming VG, Horswood RL, Chanock RM. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res 1985; 3: 193-206.
17. Hemming VG, Prince GA, Horswood RL et al. Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model. J Infect Dis 1985; 152: 1083-1087.
18. Hemming VG, Rodriguez W, Kim HW et al. Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children. Antimicrobial Agents Chemother 1987; 31: 1882-1886.
19. Hemming VG, Prince GA, Rodriguez W et al. Respiratory syncytial virus infections and intravenous gamma-globulins. Pediatr Infect Dis J 1988; 7: S103-S106.
20. Hemming VG, Prince GA. Passive immunization for the protection of infants and young children from respiratory infection by respiratory syncytial virus. In: Imbach P (ed). Immunotherapy with Intravenous Immunoglobulins. Academic Press: New York, 1991, pp 103-112.
21. Groothuis JR, Levin MJ, Rodriguez W et al. Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. Antimicrob Agents Chemother 1991; 35: 1469-1473.
22. Siber GR, Leszcynski J, Pena-Cruz V et al. Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay. J Infect Dis 1992; 165: 456-463.
23. Siber GR, Snydman DR. Use of immune globulins in the prevention and treatment of infections. In: Remington JS, Swartz MN (eds). Current Clinical Topics in Infections Diseases. Blackwell Scientific Publications: Boston, 1992, pp 208-256.
24. Siber GR, Leombruno D, Leszcynski J et al. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J Infect Dis 1993; 169: 1368-1373.
25. Graham BS, Davis TH, Tang YW, Gruber WC. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infected mice with respiratory syncytial virus specific immune serum. Pediatr Res 1993; 34: 167-172.
26. Meissner HC, Fulton DR, Groothuis JR et al. Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin. Antimicrob Agents Chemother 1993; 37: 1655-1658.
27. Groothuis JR, Simoes EAF, Levin MJ et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. New Engl J Med 1993; 329: 1524-1530.
28. Groothuis JR, Simoes EAF, Hemming VG et al. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Pediatrics 1995; 95: 463-467.
29. De Vincenzo JP, Leombruno D, Soiffer RJ, Siber GR. Immunotherapy of respiratory syncytial virus pneumonia following bone marrow transplantation. Bone Marrow Transplant 1996; 17: 1051-1056.
30. Rodriquez WJ, Gruber WC, Welliver RC et al. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections. Pediatrics 1997; 99: 454-461.
31. The Prevent Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997; 99: 93-99.
32. American Academy of Pediatrics. Prevention of respiratory syncytial virus infections: indications for the use of Palivizumab and update on the use of RSV-IGIV. Pediatrics 1998; 102: 1211-1216.
33. The Impact-RSV study group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531-537.
34. McColl MD, Corser RB, Bremner J, Chopra R. Respiratory syncytial virus infection in adult BMT recipients: effective therapy with short duration nebulised ribavirin. Bone Marrow Transplant 1998; 21: 423-425.